SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, disclosed that its HemopurifierTM treatment technology is referenced in a Special Biodefense Report published in the latest of issue of New Scientist Magazine. The report entitled, “Fortress America” discusses how Americans are still as vulnerable as ever to the threat of bioterrorism, even after the deployment of massive spending programs to develop traditional drug and vaccine treatments for bioterror threats. The report highlights how programs, including the $5.6 billion Project Bioshield initiative, will need to transition to broad-spectrum therapeutics in order to address known and unknown bioterror threats. The Aethlon HemopurifierTM is a broad-spectrum countermeasure against pandemic threats, including biological weapons.
